Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SZSE:002399 Stock Report

Market Cap: CN¥14.5b

Shenzhen Hepalink Pharmaceutical Group Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Yu Shan

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentage49.5%
CEO tenure26.6yrs
CEO ownershipn/a
Management average tenure2.4yrs
Board average tenure13.7yrs

Recent management updates

Recent updates

Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Oct 07
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio

Aug 22
Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio

Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Jun 12
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues

May 06
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues

CEO Compensation Analysis

How has Yu Shan's remuneration changed compared to Shenzhen Hepalink Pharmaceutical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CN¥146m

Jun 30 2024n/an/a

-CN¥243m

Mar 31 2024n/an/a

-CN¥695m

Dec 31 2023CN¥3mCN¥1m

-CN¥783m

Sep 30 2023n/an/a

CN¥218m

Jun 30 2023n/an/a

CN¥340m

Mar 31 2023n/an/a

CN¥559m

Jan 01 2023n/an/a

CN¥727m

Sep 30 2022n/an/a

CN¥432m

Jun 30 2022n/an/a

CN¥414m

Mar 31 2022n/an/a

CN¥332m

Jan 01 2022n/an/a

CN¥241m

Sep 30 2021n/an/a

CN¥777m

Jun 30 2021n/an/a

CN¥781m

Mar 31 2021n/an/a

CN¥912m

Dec 31 2020CN¥5mCN¥2m

CN¥1b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥1b

Mar 31 2020n/an/a

CN¥808m

Dec 31 2019CN¥2mCN¥2m

CN¥1b

Compensation vs Market: Yu's total compensation ($USD365.42K) is above average for companies of similar size in the CN market ($USD165.22K).

Compensation vs Earnings: Yu's compensation has increased whilst the company is unprofitable.

CEO

Yu Shan (64 yo)

26.6yrs

Tenure

CN¥2,647,000

Compensation

Mr. Yu Shan co-founded Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in April 1998 and has been its General Manager since April 21, 1998 and serves as its Group Vice President. From August 1982 to Febru...

Leadership Team

NamePositionTenureCompensationOwnership
Li Li
Co-Founder26.6yrsCN¥2.98mno data
Yu Shan
Co-Founder26.6yrsCN¥2.65mno data
Juan Chen
VP of Finance1.3yrsCN¥992.60kno data
Tan Li
VP, Deputy GM & Directorno dataCN¥2.45mno data
Fengqi Qian
Company Secretary3.1yrsCN¥1.67mno data
Tao Han
Chief Business Officerno datano datano data
Xi Gao
Senior Vice President of Global Supply Chain1.7yrsno datano data

2.4yrs

Average Tenure

60yo

Average Age

Experienced Management: 002399's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Li Li
Co-Founder26.6yrsCN¥2.98mno data
Yu Shan
Co-Founder26.6yrsCN¥2.65mno data
Tan Li
VP, Deputy GM & Director26.6yrsCN¥2.45mno data
Haijun Tang
Supervisor16.9yrsno datano data
Jilan Su
Employee Supervisor16.9yrsno datano data
Zehui Zheng
Chairman of Supervisory Board10.5yrsno datano data
Chuan Lu
Independent Non-Executive Director4.9yrsCN¥100.00kno data
Israel Vlodavsk
Chairman of Hepalink’s Scientific Advisory Boardno datano datano data
Nathan Karin
Member of Hepalink’s Scientific Advisory Boardno datano datano data
Ping Zhang
Director1.5yrsCN¥3.49mno data
Ming Yi
Independent Non-Executive Director1.5yrsCN¥58.00kno data
Peng Huang
Independent Non-Executive Director1.5yrsCN¥58.00kno data

13.7yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 002399's board of directors are seasoned and experienced ( 13.7 years average tenure).